CN113402609B - 具有经修饰的ch2-ch3序列的犬抗体 - Google Patents

具有经修饰的ch2-ch3序列的犬抗体 Download PDF

Info

Publication number
CN113402609B
CN113402609B CN202110533946.4A CN202110533946A CN113402609B CN 113402609 B CN113402609 B CN 113402609B CN 202110533946 A CN202110533946 A CN 202110533946A CN 113402609 B CN113402609 B CN 113402609B
Authority
CN
China
Prior art keywords
seq
canine
ser
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110533946.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113402609A (zh
Inventor
M.莫塞
张远征
I.塔佩伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Priority to CN202110533946.4A priority Critical patent/CN113402609B/zh
Publication of CN113402609A publication Critical patent/CN113402609A/zh
Application granted granted Critical
Publication of CN113402609B publication Critical patent/CN113402609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202110533946.4A 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体 Active CN113402609B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110533946.4A CN113402609B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361918847P 2013-12-20 2013-12-20
US201361918946P 2013-12-20 2013-12-20
US61/918946 2013-12-20
US61/918847 2013-12-20
US201462030812P 2014-07-30 2014-07-30
US62/030812 2014-07-30
CN202110533946.4A CN113402609B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体
PCT/EP2014/078653 WO2015091910A2 (fr) 2013-12-20 2014-12-19 Anticorps caninises
CN201480075969.3A CN106029697B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480075969.3A Division CN106029697B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体

Publications (2)

Publication Number Publication Date
CN113402609A CN113402609A (zh) 2021-09-17
CN113402609B true CN113402609B (zh) 2023-12-05

Family

ID=52273133

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202311519683.7A Pending CN117603354A (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体
CN202110533910.6A Active CN113173993B (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体
CN201480075969.3A Active CN106029697B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体
CN201480069679.8A Active CN105829344B (zh) 2013-12-20 2014-12-19 犬化鼠抗犬pd-1抗体
CN202410327917.6A Pending CN117986366A (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体
CN201480075559.9A Active CN106029695B (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体
CN202110533946.4A Active CN113402609B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体

Family Applications Before (6)

Application Number Title Priority Date Filing Date
CN202311519683.7A Pending CN117603354A (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体
CN202110533910.6A Active CN113173993B (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体
CN201480075969.3A Active CN106029697B (zh) 2013-12-20 2014-12-19 具有经修饰的ch2-ch3序列的犬抗体
CN201480069679.8A Active CN105829344B (zh) 2013-12-20 2014-12-19 犬化鼠抗犬pd-1抗体
CN202410327917.6A Pending CN117986366A (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体
CN201480075559.9A Active CN106029695B (zh) 2013-12-20 2014-12-19 拮抗性抗犬pd-1抗体

Country Status (13)

Country Link
US (9) US10023636B2 (fr)
EP (4) EP3083694B1 (fr)
JP (7) JP6681832B2 (fr)
CN (7) CN117603354A (fr)
AU (6) AU2014368453B2 (fr)
BR (2) BR112016014293B1 (fr)
CA (5) CA3154540A1 (fr)
DK (1) DK3083694T3 (fr)
ES (1) ES2969350T3 (fr)
FI (1) FI3083694T3 (fr)
PT (1) PT3083694T (fr)
RU (4) RU2676158C1 (fr)
WO (3) WO2015091914A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603354A (zh) 2013-12-20 2024-02-27 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
PT3277722T (pt) 2015-04-02 2021-10-06 Intervet Int Bv Anticorpos para recetor alfa da interleucina-4 canina
WO2017011580A2 (fr) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
BR112018000917A2 (pt) 2015-07-16 2018-09-11 Bioxcel Therapeutics Inc abordagem inovadora para o tratamento de câncer através da imunomodulação
KR20180057637A (ko) * 2015-08-31 2018-05-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개의 암을 치료하기 위한 키메라 aav-항-vegf
EP3344656A1 (fr) 2015-09-01 2018-07-11 Agenus Inc. Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
CA3005696A1 (fr) * 2015-12-18 2017-06-22 Intervet International B.V. Anticorps humains caninises diriges contre l'il-4r alpha humaine et canine
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
EP3498838A4 (fr) * 2016-08-15 2020-01-08 National University Corporation Hokkaido University Anticorps anti-pd-l1
CN109790534A (zh) * 2016-08-15 2019-05-21 国立大学法人北海道大学 抗pd-1抗体
WO2018073185A1 (fr) * 2016-10-17 2018-04-26 Vetoquinol Sa Région constante modifiée d'un anticorps
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
MX2019010999A (es) * 2017-03-29 2020-02-05 Celgene Corp Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
GB2578867A (en) * 2018-10-09 2020-06-03 Genome Res Ltd Animal models and therapeutic molecules
EP3864049A1 (fr) 2018-10-11 2021-08-18 Inhibrx, Inc. Anticorps pd-1 à domaine unique et compositions thérapeutiques associées
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
WO2020103885A1 (fr) * 2018-11-19 2020-05-28 Beijing Biocytogen Co., Ltd Anticorps anti-pd-1 et leurs utilisations
JPWO2020116560A1 (ja) * 2018-12-05 2021-10-21 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
MX2021007680A (es) * 2018-12-27 2021-10-13 Kindred Biosciences Inc Variantes de igg fc para uso veterinario.
CN113087797B (zh) * 2019-06-03 2021-12-31 北京希诺谷生物科技有限公司 抗犬pd-1抗体及其应用
CA3145347A1 (fr) 2019-07-15 2021-01-21 Intervet International B.V. Anticorps caninises diriges contre ctla-4 humaine et canine
WO2021009187A1 (fr) * 2019-07-15 2021-01-21 Intervet International B.V. Anticorps caninisés contre le ctla-4 canin
US11629190B2 (en) 2019-08-15 2023-04-18 Oregon State University Canine antibody therapeutic for treating cancer
CN110590959B (zh) * 2019-09-19 2021-01-05 北京伟杰信生物科技有限公司 重组犬pd-1融合蛋白及其制备方法与应用
AU2020409583A1 (en) 2019-12-20 2022-06-09 Intervet International B.V. Canine interleukin-4 receptor alpha antibodies
JP2023506922A (ja) 2019-12-20 2023-02-20 インターベット インターナショナル ベー． フェー． アトピー性皮膚炎を処置するための二重特異性イヌ化抗体
JP2023513952A (ja) 2020-02-19 2023-04-04 アディボ ゲーエムベーハー 改変Ｆｃ領域
US20240067738A1 (en) * 2020-03-18 2024-02-29 Elanco Us Inc. Anti-il4 receptor antibodies for veterinary use
MX2023004438A (es) 2020-10-15 2023-05-08 Intervet Int Bv Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023021170A2 (fr) 2021-08-20 2023-02-23 Intervet International B.V. Protéines de fusion pour traiter la dermatite atopique
CA3227716A1 (fr) 2021-08-20 2023-02-23 Intervet International B.V. Anticorps et proteines de fusion igg presentant une demi-vie accrue
WO2023108138A1 (fr) * 2021-12-10 2023-06-15 The Trustees Of The University Of Pennsylvania Anticorps anti-pd-1 canin entièrement canins et leurs utilisations
WO2023111153A1 (fr) 2021-12-16 2023-06-22 Intervet International B.V. Anticorps caninisés dirigés contre ngf humain
WO2023111148A1 (fr) 2021-12-16 2023-06-22 Intervet International B.V. Anticorps caninisés contre récepteur alpha 1 de l'interleukine-31 canine
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083174A2 (fr) * 2006-12-27 2008-07-10 Emory University Compositions et procédés pour le traitement d'infections et de tumeurs
WO2013124666A1 (fr) * 2012-02-22 2013-08-29 Nvip Pty Ltd Protéines de fusion du récepteur du facteur de nécrose tumoral et ses procédés d'utilisation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69334305D1 (de) 1992-08-21 2010-01-28 Univ Bruxelles Immunoglobuline ohne leichte Ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
EP1268794A2 (fr) 2000-04-07 2003-01-02 Heska Corporation Compositions et methodes en rapport avec des recepteurs canins d'immunoglobuline g (igg) et d'il-13
NZ543512A (en) 2000-06-28 2008-12-24 Genetics Inst Llc Interaction of PD-L2 with PD-1 transmits a negative signal to immune cells, downregulating immune responses
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002079499A1 (fr) 2001-04-02 2002-10-10 Wyeth Le pd-1, recepteur du b7-4, et ses utilisations
CA2466279A1 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
JP2005514063A (ja) 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
PT1537878E (pt) * 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
AU2005224267B2 (en) 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
RU2406760C3 (ru) * 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2010512744A (ja) 2006-12-14 2010-04-30 シェーリング−プラウ・リミテッド イヌの胸腺間質リンホポエチンタンパク質およびその使用
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
EP2331579B1 (fr) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Anticorps monoclonaux
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN104479018B (zh) * 2008-12-09 2018-09-21 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) * 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
EP2413969A4 (fr) 2009-03-30 2012-09-05 Boehringer Ingelheim Int Protéines hybrides comprenant des portions fc d'anticorps canins
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
US8652470B2 (en) 2010-03-04 2014-02-18 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN107854439A (zh) 2011-03-31 2018-03-30 默沙东公司 针对人程序性死亡受体pd‑1的抗体的稳定制剂和有关的治疗
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
EP3502136A1 (fr) 2011-05-06 2019-06-26 Nexvet Australia Pty Ltd Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation
EP3498732B1 (fr) 2011-05-06 2021-11-17 Zoetis Services LLC Anticorps contre le facteur de croissance neuronale et leurs procédés de préparation et d'utilisation
US9580496B2 (en) 2011-05-06 2017-02-28 Nexvet Australia Pty Ltd Therapeutic canine immunoglobulins and methods of using same
CA2835094C (fr) 2011-05-06 2020-12-22 David Gearing Anticorps contre le facteur de croissance neuronale et leurs procedes de preparation et d'utilisation
TR201104773A1 (tr) * 2011-05-16 2013-01-21 Yeşi̇l İsmet Belaltı giysisi.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013030568A1 (fr) 2011-08-30 2013-03-07 Nvip Pty Ltd Anticorps caninisés contre le facteur de nécrose tumorale et leurs procédés d'utilisation
CA2851758A1 (fr) * 2011-10-13 2013-04-18 Nvip Pty Ltd Epitope de liaison cd20 felin/canin et compositions se liant a celui-ci
JP6316195B2 (ja) 2011-10-26 2018-04-25 エランコ ティーアゲズンタイト アーゲー モノクローナル抗体および使用の方法
JP6062748B2 (ja) 2013-01-22 2017-01-18 株式会社パイロットコーポレーション 水性ボールペン
CA3080200A1 (fr) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anticorps anti-pd1 et leur utilisation comme produits therapeutiques et produits de diagnostic
CN117603354A (zh) 2013-12-20 2024-02-27 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
TW201613635A (en) * 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
EP3168236B1 (fr) 2014-07-09 2019-09-04 Nippon Zenyaku Kogyo Co., Ltd. Anticorps anti-pd-1 canin ou anticorps anti-pd-l1 canin
US10550194B2 (en) * 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083174A2 (fr) * 2006-12-27 2008-07-10 Emory University Compositions et procédés pour le traitement d'infections et de tumeurs
WO2013124666A1 (fr) * 2012-02-22 2013-08-29 Nvip Pty Ltd Protéines de fusion du récepteur du facteur de nécrose tumoral et ses procédés d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PD-1 as a potential target in cancer therapy;David F.McDernott等;Cancer Medicine;第2卷(第5期);662-673 *
Programmed Death 1-Mediated T Cell Exhaustion during Visceral Leishmaniasis Impairs Phagocyte Function;Kevin J.Esch等;The Journal of Immunology;第191卷(第11期);542-555 *

Also Published As

Publication number Publication date
EP4124624A3 (fr) 2023-05-03
RU2016129280A (ru) 2018-01-25
RU2016129113A (ru) 2018-01-25
PT3083694T (pt) 2024-02-01
US11680097B2 (en) 2023-06-20
JP2017500867A (ja) 2017-01-12
BR112016014293A2 (pt) 2017-12-05
US10023636B2 (en) 2018-07-17
RU2019102939A (ru) 2019-03-28
WO2015091911A3 (fr) 2015-10-15
CN113173993A (zh) 2021-07-27
EP3083693A2 (fr) 2016-10-26
AU2014368449A1 (en) 2016-07-07
AU2014368449C1 (en) 2021-05-06
AU2020210142B2 (en) 2024-01-25
BR112016014277A2 (pt) 2018-01-09
RU2676158C1 (ru) 2018-12-26
RU2761663C2 (ru) 2021-12-13
AU2020210142A1 (en) 2020-08-13
AU2021200946A1 (en) 2021-03-11
RU2019111899A (ru) 2019-10-03
US20200354450A1 (en) 2020-11-12
US20220204615A1 (en) 2022-06-30
AU2014368450B2 (en) 2020-05-07
CN113173993B (zh) 2024-03-08
JP6681832B2 (ja) 2020-04-15
CN117603354A (zh) 2024-02-27
CN113402609A (zh) 2021-09-17
JP2017500866A (ja) 2017-01-12
RU2020129387A (ru) 2020-10-08
US9944704B2 (en) 2018-04-17
EP3083693B1 (fr) 2022-09-21
RU2687209C1 (ru) 2019-05-07
CN106029695A (zh) 2016-10-12
WO2015091910A3 (fr) 2015-08-20
EP4124624A2 (fr) 2023-02-01
CN117986366A (zh) 2024-05-07
JP7142618B2 (ja) 2022-09-27
CN105829344A (zh) 2016-08-03
US20160333096A1 (en) 2016-11-17
US20240084004A1 (en) 2024-03-14
DK3083694T3 (da) 2024-01-29
BR112016014284A2 (pt) 2017-12-05
AU2023285870A1 (en) 2024-01-18
CA3154540A1 (fr) 2015-06-25
CA2932567C (fr) 2023-01-10
RU2732604C2 (ru) 2020-09-21
CA2932519C (fr) 2023-03-07
CN106029695B (zh) 2021-06-04
RU2020129387A3 (fr) 2021-02-26
CN105829344B (zh) 2021-12-07
US10927172B2 (en) 2021-02-23
AU2014368449B2 (en) 2020-11-12
JP2020014476A (ja) 2020-01-30
FI3083694T3 (fi) 2024-02-09
BR112016014293B1 (pt) 2023-11-21
JP2022180448A (ja) 2022-12-06
CN106029697B (zh) 2021-06-04
US20160319018A1 (en) 2016-11-03
CA2932567A1 (fr) 2015-06-25
AU2014368450A1 (en) 2016-07-07
EP3083685A2 (fr) 2016-10-26
ES2969350T3 (es) 2024-05-17
EP3083694B1 (fr) 2023-11-22
RU2016129274A (ru) 2018-01-25
US10106607B2 (en) 2018-10-23
JP2020031653A (ja) 2020-03-05
JP2020072727A (ja) 2020-05-14
WO2015091911A2 (fr) 2015-06-25
EP3083694A2 (fr) 2016-10-26
WO2015091910A2 (fr) 2015-06-25
US11248047B2 (en) 2022-02-15
CA2932515C (fr) 2023-08-01
CA3185195A1 (fr) 2015-06-25
US20180251554A1 (en) 2018-09-06
AU2014368453B2 (en) 2020-04-16
US20190002562A1 (en) 2019-01-03
JP2017501168A (ja) 2017-01-12
JP6974409B2 (ja) 2021-12-01
WO2015091914A2 (fr) 2015-06-25
CN106029697A (zh) 2016-10-12
JP6622703B2 (ja) 2019-12-18
US10711061B2 (en) 2020-07-14
US20160311902A1 (en) 2016-10-27
JP6701079B2 (ja) 2020-05-27
AU2014368453A1 (en) 2016-07-07
WO2015091914A3 (fr) 2015-09-03
US20180346570A1 (en) 2018-12-06
CA2932515A1 (fr) 2015-06-25
CA2932519A1 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
CN113402609B (zh) 具有经修饰的ch2-ch3序列的犬抗体
AU2021218094B2 (en) PD-L1 antibodies binding canine PD-L1
RU2750675C1 (ru) Антитела против pd-1 и композиции
KR102161460B1 (ko) St2 항원 결합 단백질
KR102614189B1 (ko) Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
KR102435081B1 (ko) 종양 치료용 항체 조성물
CN113861294B (zh) 针对犬白介素-4受体α的抗体
KR20210084587A (ko) 다가 조절 t 세포 조정제
KR20240024318A (ko) T 세포 활성화 이중특이적 항원 결합 분자 CD3 ABD 엽산 수용체 1(FolR1) 및 PD-1 축 결합 길항물질의 조합 요법
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20190069437A (ko) Cd123 결합 단백질 그리고 관련된 조성물 및 방법
TW202227492A (zh) 抗切斷型突變calr-cd3雙特異性抗體及醫藥組合物
KR20230132468A (ko) Npr1 작용제에 결합하는 면역글로불린 단백질
TW202227495A (zh) 用於調節β鏈介導之免疫的方法及組成物
TW202021616A (zh) 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
RU2801209C2 (ru) Собачьи антитела с модифицированными последовательностями ch2-ch3
RU2815059C2 (ru) Собачьи антитела с модифицированными последовательностями ch2-ch3
KR20230110523A (ko) 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
CN117337306A (zh) 靶向pd-l1和cd73的特异性结合蛋白
CN117460747A (zh) 靶向CD79b、CD20和CD3的三特异性抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant